The Pathology Research Core (PRC) provides high quality histology-related services, performed within a quality system based on CLIA standards, including preparation of microscopy slides, tissue microarray construction, immunostaining, digital image capture and analysis, laser capture microdissection, and preparation of tissues for subsequent nucleic acid or protein extraction. Most services are performed using clinical diagnostic tissues, allowing Mayo Clinic Cancer Center (MCCC) investigators to take advantage of the wealth of clinical materials for biomarker discovery and validation. PRC is a critical asset in the translation of basic biology to clinical relevance by MCCC members. The Shared Resource Advisory Committee-B reviews with the PRC Director the operations, fee structure, budget, utilization, and user-satisfaction on an annual basis. MCCC leadership works with the Institutional Research Core Subcommittee to provide financial support to PRC. Dr. Flotte has 30 years'experience with research pathology as an NIH funded investigator and as research laboratory director. He has been a principal investigator, a pathology core director, space committee chair, and SPORE executive committee member. The PRC supervisor has a 4-year college degree in molecular biology and extensive management training courses through Mayo Office of Leadership and Organization Development. In 2012, PRC completed 1,122 requests for work from 173 users, 116 (67%) of whom were MCCC members. Fifty-one members had peer-reviewed support. Access to services provided by PRC is open to all Mayo investigators, including MCCC members, on a first come, first served basis. Chargebacks are structured to ensure that federally funded Mayo investigators, including MCCC members, have the lowest rates, as is required by federal regulations. Antibody optimization is fully subsidized by the MCCC for Cancer Center members. In comparison of PRC rates with 5 other academic institutions, PRC rates are significantly less than average for 9 of 11 services and within range for the other 2 services. Hours of operation are from 7:00 am to 6:00 pm Monday through Friday. Work requests can be submitted electronically at any time. Technical staff includes 9 FTE. The PRC is now located at MCR, MCA, and MCF.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682937
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$114,282
Indirect Cost
$42,474
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97

Showing the most recent 10 out of 340 publications